Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 Shares of Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $30.42, for a total value of $1,064,700.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Robert Berman also recently made the following trade(s):

  • On Wednesday, January 10th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $27.52, for a total value of $963,200.00.
  • On Tuesday, December 19th, Robert Berman sold 10,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $24.10, for a total value of $241,000.00.
  • On Monday, December 11th, Robert Berman sold 25,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $21.28, for a total value of $532,000.00.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) traded down $0.19 during mid-day trading on Thursday, reaching $29.71. The company had a trading volume of 47,385 shares, compared to its average volume of 419,164. Biohaven Pharmaceutical Holding Co Ltd has a 12-month low of $17.00 and a 12-month high of $39.51. The stock has a market cap of $1,080.00 and a price-to-earnings ratio of -5.73.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its earnings results on Tuesday, November 14th. The company reported ($1.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.03. equities research analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of BHVN. Deschutes Portfolio Strategy LLC purchased a new stake in Biohaven Pharmaceutical in the 3rd quarter valued at approximately $374,000. Strs Ohio purchased a new stake in Biohaven Pharmaceutical in the 3rd quarter valued at approximately $680,000. Nationwide Fund Advisors purchased a new stake in Biohaven Pharmaceutical in the 3rd quarter valued at approximately $214,000. Emerald Advisers Inc. PA purchased a new stake in Biohaven Pharmaceutical in the 3rd quarter valued at approximately $9,096,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in Biohaven Pharmaceutical in the 3rd quarter valued at approximately $7,483,000. 48.09% of the stock is currently owned by hedge funds and other institutional investors.

BHVN has been the topic of several research analyst reports. BidaskClub lowered Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, October 27th. Needham & Company LLC reissued a “buy” rating and set a $36.00 price target on shares of Biohaven Pharmaceutical in a research note on Wednesday, November 15th. Zacks Investment Research raised Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Monday, December 4th. Piper Jaffray Companies set a $48.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, December 11th. Finally, Canaccord Genuity initiated coverage on Biohaven Pharmaceutical in a research note on Friday, December 15th. They set a “buy” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. Biohaven Pharmaceutical currently has an average rating of “Buy” and an average price target of $36.14.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://weekherald.com/2018/02/15/biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-robert-berman-sells-35000-shares-of-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply